With chronic diseases rising across the region and healthcare systems under growing strain, the need for more proactive, data-driven patient care has never been more urgent. That’s where Mesh Bio comes in. Its digital health platforms help clinicians spot risks earlier and make more informed decisions, moving care upstream rather than reacting only when complications surface.

On this episode of the 2025 OCBC Emerging Enterprise series, Dr. Andrew Wu, Co-Founder and CEO of Mesh Bio and one of this year’s Emerging Enterprise Award winners, shares how his company is transforming chronic disease management, the realities of scaling health-tech across diverse markets, and the opportunities they see in shaping the future of predictive, precision-driven healthcare.

With chronic diseases rising across the region and healthcare systems under growing strain, the need for more proactive, data-driven patient care has never been more urgent. That&rsquo;s where Mesh Bio comes in. Its digital health platforms help clinicians spot risks earlier and make more informed decisions, moving care upstream rather than reacting only when complications surface.
On this episode of the 2025 OCBC Emerging Enterprise series,&nbsp;Dr. Andrew Wu, Co-Founder and CEO of Mesh Bio and one of this year&rsquo;s Emerging Enterprise Award winners, shares how his company is transforming chronic disease management, the realities of scaling health-tech across diverse markets, and the opportunities they see in shaping the future of predictive, precision-driven healthcare.

The 2025 Emerging Enterprise Awards recognise the bold ambitions of young businesses in Singapore and the region. It’s a celebration of business innovation, resilience and excellence.

The 2025 Emerging Enterprise Awards recognise the bold ambitions of young businesses in Singapore and the region. It&rsquo;s a celebration of business innovation, resilience and excellence.

Advertisement